Stock USRM U.S. STEM CELL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials U.S. Stem Cell, Inc.

Equities

USRM

US90350U1007

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 20:42:59 02/05/2024 BST 		5-day change 1st Jan Change
0.000001 USD -99.00% Intraday chart for U.S. Stem Cell, Inc. 0.00% 0.00%
2023 U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2023 U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 9.921 6.049 1.462 5.314 3.021 3.045
Enterprise Value (EV) 1 14.2 9.978 8.155 13.64 11.95 13.12
P/E ratio -2.57 x -2.71 x -0.36 x -1.81 x -0.84 x -0.99 x
Yield - - - - - -
Capitalization / Revenue 1.8 x 0.9 x 0.48 x 19.2 x 15 x 37.1 x
EV / Revenue 2.57 x 1.49 x 2.65 x 49.2 x 59.5 x 160 x
EV / EBITDA -22.7 x -11.2 x -3.29 x -6.32 x - -
EV / FCF 42.8 x 72.7 x -5.93 x -20.7 x -14.7 x -45.1 x
FCF Yield 2.34% 1.38% -16.9% -4.83% -6.81% -2.22%
Price to Book -1.4 x -0.88 x -0.15 x -0.46 x -0.24 x -0.21 x
Nbr of stocks (in thousands) 342,113 378,077 417,725 435,561 503,525 634,403
Reference price 2 0.0290 0.0160 0.003500 0.0122 0.006000 0.004800
Announcement Date 16/04/18 13/03/19 16/07/21 16/07/21 31/03/22 14/04/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 5.521 6.701 3.072 0.2771 0.2007 0.082
EBITDA 1 -0.6259 -0.8908 -2.475 -2.158 - -
EBIT 1 -0.8047 -1.098 -2.718 -2.4 -2.136 -1.72
Operating Margin -14.58% -16.38% -88.47% -866.24% -1,063.94% -2,096.9%
Earnings before Tax (EBT) 1 -3.481 -2.16 -3.835 -2.89 -3.287 -2.858
Net income 1 -3.481 -2.16 -3.835 -2.89 -3.287 -2.858
Net margin -63.06% -32.24% -124.84% -1,043.17% -1,637.58% -3,483.21%
EPS 2 -0.0113 -0.005908 -0.009635 -0.006733 -0.007134 -0.004831
Free Cash Flow 1 0.3318 0.1373 -1.376 -0.6592 -0.814 -0.2911
FCF margin 6.01% 2.05% -44.77% -237.91% -405.46% -354.81%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 16/04/18 13/03/19 16/07/21 16/07/21 31/03/22 14/04/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 4.28 3.93 6.69 8.33 8.93 10.1
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -6.838 x -4.411 x -2.704 x -3.86 x - -
Free Cash Flow 1 0.33 0.14 -1.38 -0.66 -0.81 -0.29
ROE (net income / shareholders' equity) 46.1% 30.9% 46.9% 27.5% 27% 20.8%
ROA (Net income/ Total Assets) -49.7% -40.2% -178% -1,686% -1,919% -1,807%
Assets 1 7.012 5.376 2.153 0.1715 0.1713 0.1582
Book Value Per Share 2 -0.0200 -0.0200 -0.0200 -0.0300 -0.0300 -0.0200
Cash Flow per Share 2 0 0 - 0 0 0
Capex 1 0 - - - - -
Capex / Sales 0.02% - - - - -
Announcement Date 16/04/18 13/03/19 16/07/21 16/07/21 31/03/22 14/04/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
U.S. STEM CELL, INC. Stock U.S. Stem Cell, Inc.
0.00% 661
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.93% 106B
ARGENX SE Stock argenx SE
+7.02% 23.47B
BIONTECH SE Stock BioNTech SE
-14.60% 21.9B
GENMAB A/S Stock Genmab A/S
-7.05% 18.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.85B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.83% 16.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.51% 14.41B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.49% 12.86B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+329.39% 8.78B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. USRM Stock
  4. Financials U.S. Stem Cell, Inc.